The Flu Vaccine Study
The study drug is a new mRNA vaccine against influenza (flu vaccine).
This vaccine uses mRNA technology to send a set of instructions to the cells in the body to develop an antigen. These antigens will trigger an immune response, which will enable the immune system to protect itself against influenza.
The vaccine does not contain any live components of the flu virus and you will not be infected with influenza during the study. Participants will receive a single dose of the vaccine.
The flu can cause severe complications such as pneumonia, particularly in older adults and those who suffer from chronic diseases, lung disease, and heart disease.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.